Boston Scientific Corp BSX.US

Boston Scientific Corporation specialises in the development, manufacture and marketing of devices for use in interventional medical practices. Founded in June 1979, the company has headquarters in Marlborough, Massachusetts. The company provides innovative solutions to improve the wellbeing of patients all around the world.

Boston Scientific’s products are designed to be minimally invasive, enabling surgery patients to recover more rapidly. The business operates through three segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro sector develops implantable devices designed for heart monitoring and regulating rhythmical abnormalities via electrical charges. The Cardiovascular sector is involved in the development of technologies for investigating and treating cardiovascular disorders. The company’s MedSurg sector includes Endoscopy and Urology and Pelvic Health, including the development and manufacture of equipment for the diagnosis and treatment of pulmonary and gastrointestinal abnormalities and devices to treat urological and pelvic conditions.

Boston Scientific’s stock trades on the NYSE under the BSX.US ticker. On 6 October 2021, Boston Scientific announced the acquisition of Baylis Medical Company Inc, a privately held medical device maker, in a deal for $1.75bn. The acquisition was expected to expand the company’s heart and electrophysiology product portfolios.

Track the performance of BSX.US stock by adding it to your eToro watchlist.